Home / Resources / A Steady Flow Toward Approval: Key Potential Drug Launches in 2025

A Steady Flow Toward Approval: Key Potential Drug Launches in 2025

Infographic
Commercial
Citeline Commercial Infographic: A Steady Flow Toward Approval

Key Potential Drug Launches in 2025

According to Biomedtracker’s Key Potential Drug Launches in 2025 report, the pipeline is set to deliver 69 key launches across 66 discrete drugs next year.* This is roughly the same number as predicted for 2024 back in July 2023.

*Data as of July 2024

Related products
Expert analyst presenting data insights on a projected screen.
Biomedtracker
Real-time tracking and analysis of the drug development pipeline
Analyst using Datamonitor Healthcare for a market assesment.
Datamonitor Healthcare
Analysis and data tools for pharma market assessments without the guesswork
Healthcare professional monitoring and analyzing R and D trends.
Pharmaprojects
The industry standard for tracking and analyzing the global drug R&D landscape

Related resources

A variety of pills and tablets arranged neatly on a wooden table surface
OCT 09, 2024
Report
Commercial

Key Potential Drug Launches in 2025

Biomedtracker’s Key Potential Drug Launches in 2025 report provides a longer-term look at some key late-stage drugs projected to hit the market in 2025.

Citeline professional presenting the Q4 2024 Outlook Report provided by Biomedtracker.
SEP 30, 2024
Report
Commercial

Q4 Outlook Report: Key Industry Drugs, Devices & Deals

In this report, we cover catalysts from 24 drugs, devices, diagnostics, and deals expected to occur in Q4 2024.

Stacks of coins arranged in ascending order with a white arrow and line graph overlay indicating growth
JUN 11, 2024
eBook
Commercial

Billion Dollar Blueprint: The Journey to Blockbuster Status

A deep dive into the dynamics of blockbuster drugs. Using data from Evaluate Pharma, Scrip surveys the existing field of these top-tier products, examines the role that multiple indications play and the time it takes to reach blockbuster status, and considers whether there is an advantage for in-house or external assets.

View all